Pharmaceutical Technology

NOVEMBER 9, 2022

Known by the brand name Roctavian, BioMarin’s haemophilia A therapy valoctocogene roxaparvovec could be fairly priced in the range of $1.95–1.96 BioMarin’s Roctavian has a target PDUFA action date of March 31 next year. million price tag. million, the think tank concluded in its updated evaluation. million ($1.5

Safety 111

Safety Pharmaceutical Patients Medicine 111

pharmaphorum

AUGUST 26, 2022

BioMarin Pharma has its landmark first approval for Roctavian – the first for a haemophilia gene therapy – and will now have to see if that can convert that into a viable business in Europe. BioMarin has said Roctavian will be available at a ‘net’ price of around €1.5 million spread over five years.

FDA 109

FDA Marketing Competition Patients 109

Pharmaceutical Technology

JANUARY 27, 2023

Other companies like BioMarin have already announced an intention to offer an outcomes-based warranty program for its hemophilia A drug Roctavian (valoctocogene roxaparvovec). In 2022, the number of risk sharing agreements peaked with 144 agreements being made in the pharmaceutical industry.

Patients 52

Patients Pharmaceutical Manufacturing Healthcare Provider 52